As Enhertu’s reach continues to spread into additional forms of breast cancer, Daiichi Sankyo and AstraZeneca are ramping up ...

Merck MRK announced that a phase study evaluating its Daiichi Sankyo-partnered HER3-directed DXd antibody drug conjugate (ADC ...

ADCs, particularly Enhertu and datopotamab deruxtecan, are showing promising results. See why I rate the stock a buy.

ASHEVILLE — After going 9-4 and reaching the third round of the NCHSAA playoffs last season, Reynolds football retooled its offense. The Rockets added IMG Academy junior transfer quarterback Ely ...

(RTTNews) - Merck & Co., Inc. (MRK) and Daiichi ... small cell lung cancer or ES-SCLC. According to the companies, an objective response rate of 54.8% was observed with Daiichi Sankyo and Merck's ...

Merck (NYSE:MRK) and Daiichi Sankyo (OTCPK:DSNKY) (OTCPK:DSKYF) on Saturday announced interim results from a Phase 2 trial for lung cancer patients treated with ifinatamab deruxtecan (I-DXd ...

The companies' positive outlooks are supported by Daiichi Sankyo's advanced Antibody-Drug Conjugate (ADC) platform and its potential for significant growth. Enhertu, a breast cancer treatment ...

ADC from Daiichi Sankyo's second ADC platform, at ESMO. "New data in lung, breast, gastric, ovarian, endometrial and other cancers from several of our DXd antibody drug conjugates demonstrates how ...

Data at WCLC and ESMO showcasing Daiichi Sankyo’s progress towards ... with pretreated extensive-stage small cell lung cancer and results from the ENHERTU ® (trastuzumab deruxtecan) monotherapy ...